BRAF and neoplasm: A comprehensive tumor molecular characterization shall be pursued where available in patients with advanced BTCs, as certain genetic alterations, such as IDH1 mutations (I,A), FGFR2 fusions (II, B), BRAF mutations (II, B), microsatellite instability (II, B), high-TMB (II, B), and NTRK rearrangements (II, B), among others, may benefit from specific targeted therapies.